PPARA and metabolic syndrome: Beginning one week after tumor inoculation and continuing for a total of 7 days, the mice received a daily intraperitoneal (i.p.)injection of either DMSO (control) or pemafibrate (Pem), a highly selective PPARα agonist used in humans for the treatment of metabolic syndrome [29, 30].